Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market By Product Type (Prolastin C, Aralast NP, Glassia, and Zemaira/Reespreza), By End-User (Hospitals, Specialty Clinics, and Pharmacies), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2023-2032
- Published date: Oct 2023
- Report ID: 95351
- Number of Pages: 370
- Format:
-
keyboard_arrow_up
-
-
- Grifols, S.A. (Spain)
- Kamada Pharmaceuticals
- CSL Limited
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd. Company Profile
- GlaxoSmithKline PLC
- Arrowhead Pharmaceutical, Inc.
- LFB Biomedicaments S.A.
- Mereo BioPharma Group plc
- Intellia Therapeutics, Inc.
- Inhibrx, Inc.
- Centessa Pharmaceuticals (Z factor)
- Krystal Biotech
- Beam Therapeutics
- LOGICBIO THERAPEUTICS, INC.
- Apic Bio
- Pfizer Inc Company Profile
- Other Key Players
- settingsSettings
Our Clients
- 95351
- Oct 2023
Trusted by more than 17382 organizations globally
✖
Request a Sample Report
We'll get back to you as quickly as possible
|
Single User
$6,000
$3,999
USD / per unit
save 24%
|
Multi User
$8,000
$5,999
USD / per unit
save 28%
|
Corporate User
$10,000
$6,999
USD / per unit
save 32%
|
|
|---|---|---|---|
| e-Access | |||
| Report Library Access | |||
| Data Set (Excel) | |||
| Company Profile Library Access | |||
| Interactive Dashboard | |||
| Free Custumization | No | up to 10 hrs work | up to 30 hrs work |
| Accessibility | 1 User | 2-5 User | Unlimited |
| Analyst Support | up to 20 hrs | up to 40 hrs | up to 50 hrs |
| Benefit | Up to 20% off on next purchase | Up to 25% off on next purchase | Up to 30% off on next purchase |
| Buy Now ($ 3,999) | Buy Now ($ 5,999) | Buy Now ($ 6,999) |
